Literature DB >> 32761324

Medical Management and Prevention of Motor Complications in Parkinson's Disease.

Stephen D Aradi1, Robert A Hauser2.   

Abstract

Levodopa is the most effective medication for the treatment of the motor symptoms of Parkinson's disease. However, over time, the clinical response to levodopa becomes complicated by a reduction in the duration and reliability of motor improvement (motor fluctuations) and the emergence of involuntary movements (levodopa-induced dyskinesia). Strategies that have been attempted in an effort to delay the development of these motor complications include levodopa sparing and continuous dopaminergic therapy. Once motor complications occur, a wide array of medical treatments is available to maximize motor function through the day while limiting dyskinesia. Here, we review the clinical features, epidemiology, and risk factors for the development of motor complications, as well as strategies for their prevention and medical management.

Entities:  

Keywords:  Parkinson’s disease; continuous dopaminergic stimulation; levodopa; levodopa-induced dyskinesia; motor fluctuations; treatment

Year:  2020        PMID: 32761324      PMCID: PMC7851275          DOI: 10.1007/s13311-020-00889-4

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  202 in total

1.  Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.

Authors:  Miho Murata; Kazuko Hasegawa; Ichiro Kanazawa
Journal:  Neurology       Date:  2007-01-02       Impact factor: 9.910

2.  Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.

Authors:  M Merello; R Pikielny; A Cammarota; R Leiguarda
Journal:  Clin Neuropharmacol       Date:  1997-04       Impact factor: 1.592

3.  Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.

Authors:  Constant V M Verschuur; Sven R Suwijn; Judith A Boel; Bart Post; Bas R Bloem; Johannes J van Hilten; Teus van Laar; Gerrit Tissingh; Alexander G Munts; Guenther Deuschl; Anthony E Lang; Marcel G W Dijkgraaf; Rob J de Haan; Rob M A de Bie
Journal:  N Engl J Med       Date:  2019-01-24       Impact factor: 91.245

4.  Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study.

Authors:  Donald G Grosset; Rohit Dhall; Tanya Gurevich; Jan Kassubek; Werner H Poewe; Olivier Rascol; Monika Rudzinska; Jennifer Cormier; Alexander Sedkov; Charles Oh
Journal:  Parkinsonism Relat Disord       Date:  2019-12-23       Impact factor: 4.891

5.  A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.

Authors:  R B Dewey; J T Hutton; P A LeWitt; S A Factor
Journal:  Arch Neurol       Date:  2001-09

6.  Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.

Authors:  D J Brooks; Y Agid; K Eggert; H Widner; K Ostergaard; A Holopainen
Journal:  Eur Neurol       Date:  2005-06-20       Impact factor: 1.710

Review 7.  Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

Authors:  S Kaakkola
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

8.  Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.

Authors:  Kelly E Lyons; Rajesh Pahwa
Journal:  Clin Neuropharmacol       Date:  2006 Mar-Apr       Impact factor: 1.592

9.  Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction.

Authors:  J P Bennett; E R Landow; S Dietrich; L A Schuh
Journal:  Mov Disord       Date:  1994-07       Impact factor: 10.338

10.  Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules.

Authors:  Nishit B Modi; Aravind Mittur; Robert Rubens; Sarita Khanna; Suneel Gupta
Journal:  Clin Neuropharmacol       Date:  2019 Jan/Feb       Impact factor: 1.592

View more
  7 in total

Review 1.  Determination of levodopa by chromatography-based methods in biological samples: a review.

Authors:  Ruiqi Jiang; Jiayu Yang; Shenghui Mei; Zhigang Zhao
Journal:  Anal Sci       Date:  2022-06-17       Impact factor: 1.967

Review 2.  Advanced molecular therapies for neurological diseases: focus on stroke, alzheimer's disease, and parkinson's disease.

Authors:  Madhumitha Katta; Blessy Aksa Mathew; Pragya Chaturvedi; Abhilash Ludhiadch; Anjana Munshi
Journal:  Neurol Sci       Date:  2022-09-06       Impact factor: 3.830

Review 3.  Novel Pharmacotherapies in Parkinson's Disease.

Authors:  Yousef Tizabi; Bruk Getachew; Michael Aschner
Journal:  Neurotox Res       Date:  2021-05-18       Impact factor: 3.911

4.  Professionals' Self-Reported Difficulties towards Integrating Dual Task Training in Care for People with Parkinson's Disease.

Authors:  Josefa Domingos; John Dean; Júlio Belo Fernandes; Catarina Godinho
Journal:  Int J Environ Res Public Health       Date:  2022-01-24       Impact factor: 3.390

5.  Mitigating Gait Decline in a Woman With Parkinson's Disease: A Case Report.

Authors:  Eric Chun-Pu Chu; Arnold Yu-Lok Wong
Journal:  J Med Cases       Date:  2022-03-05

Review 6.  Systematic review for the prevention and management of falls and fear of falling in patients with Parkinson's disease.

Authors:  Wen-Yi Liu; Tao-Hsin Tung; Chencheng Zhang; Leiyu Shi
Journal:  Brain Behav       Date:  2022-07-14       Impact factor: 3.405

7.  The Experience of OFF Periods in Parkinson's Disease: Descriptions, Triggers, and Alleviating Factors.

Authors:  Sneha Mantri; Madeline Lepore; Briana Edison; Margaret Daeschler; Catherine M Kopil; Connie Marras; Lana M Chahine
Journal:  J Patient Cent Res Rev       Date:  2021-07-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.